undamentalytics Newsletter
Sign in

Viking Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Viking Therapeutics, Inc. had total assets of $716m, total liabilities of $76.7m and shareholders' equity of $639m. It held $166m in cash against $0 of debt: net cash of $166m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents11392582926375627166678
Total current assets1151422302284256211167367907716973
Total assets3151522302284257211169368908716977
Accounts payable2112124198105382
Total current liabilities232695712922192777134
Long-term debt12—————————0251
Total debt22——00000000251
Total liabilities257695712923202877389
Shareholders' equity−229813298277244202145348880639589
Net debt (negative = net cash)11−3−9−25−8−29−26−37−56−27−166−427
Shares outstanding————72m72m73m78m78m100m112m115m128m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Viking Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Viking Therapeutics, Inc.